📇 Rhumatologue · VALENCIENNES CEDEX · (59) · Hospitalier

M VINCENT LEROY

Pourquoi vous devez consulter ce praticien

4 raisons identifiées

Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (2 thèses dirigées)
Expérience confirmée
24 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
126.7 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 VALENCIENNES CEDEX (59)HospitalierRPPS 10101366572

EnseignementExpérience confirmée

24ans d'exercice (thèse 2002)

📊 Reconnaissance scientifique : 35/100📝 177 articles publiés🇫🇷 Publications académiques françaises (8)🎓 2 thèses dirigées

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France

Archives of cardiovascular diseases · 2023

📚 16 citations🎯 RCR 2.37Top 22% NIH🩺 Clinique

Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort

JHEP reports : innovation in hepatology · 2024

📚 14 citations🎯 RCR 2.68Top 19% NIH🔓 Open Access📄 PDF gratuit ↗

Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study

ESC heart failure · 2024

📚 10 citations🎯 RCR 1.78🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Aims Predicting mortality in severe AL cardiac amyloidosis is challenging due to elevated biomarker levels and limited thresholds for stratifying severe cardiac damage. Methods and results This prospective, observational, cohort study included de novo, confirmed cardiac AL amyloidosis patients at the Henri Mondor National Reference Centre. The goal was to identify predictors of mortality to enhance prognostic stratification and improve informed decision-making regarding therapy. Over the 12-year study period, among the 233 patients included, 133 were NYHA III-IV and 179 Mayo 2004 III. The independent predictors for mortality identified were hsTnT, NT-proBNP, cardiac output, and conjugated bilirubin. A novel prognostic, conditional stratification, Mondor amyloidosis cardiac staging (MACS) was developed with biomarker cut-off values for Stage 1: hsTnT ≤ 107 ng/L and NT-proBNP ≤ 3867 ng/L (n = 77; 33%); for stage 2 NT-proBNP &gt; 3867 ng/L (n = 72; 30%). For stage 3, if troponin &gt;107 ng/L, regardless of NT-proBNP then CB 4 μmol/L, was added (n = 41; 17.5%) and stage 4: CB &gt; 4 μmol/L (n = 43; 18.5%). The median overall survival was 8 months 95% CI [2–24]. At 1 year, 102 (44%) patients died and the Kaplan–Meier median survival with MACS Stage 1 was not reached, while stage 2 was 15.2 months (95% CI [11–18]) and stage 3, 6.6 months (95% CI [1–13]). Notably, among European stage II patients, 17.1%, n = 8 were MACS stage 3 and European stage IIIb 21.4% (n = 23) were MACS stage 4. Importantly, among European stage IIIb patients 42.2% (n = 29) were classified MACS stage 4 and 12.5% n = 9 were only MACS stage 2. Conclusions The Mondor prognostic staging system, including conjugate bilirubin may significantly improve prognostic stratification for patients with severe cardiac amyloidosis.

Cookies & analyse de trafic

M VINCENT LEROY

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (24) — classées par pathologie

Transversal12

Épidémiologie & registres5

Revue générale2

Économie santé1

Qualité de vie / PROMs1

Risque cardio-vasculaire1

Santé mentale / fatigue1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche